Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inherited human ezrin deficiency impairs adaptive immunity.
García-Solís B, Van Den Rym A, Martinez-Martínez L, Franco T, Pérez-Caraballo JJ, Markle J, Cubillos-Zapata C, Marín AV, Recio MJ, Regueiro JR, Navarro-Zapata A, Mestre-Durán C, Ferreras C, Martín Cotázar C, Mena R, de la Calle-Fabregat C, López-Lera A, Fernández Arquero M, Pérez-Martínez A, López-Collazo E, Sánchez-Ramón S, Casanova JL, Martínez-Barricarte R, de la Calle-Martín O, Pérez de Diego R. García-Solís B, et al. Among authors: mestre duran c. J Allergy Clin Immunol. 2023 Oct;152(4):997-1009.e11. doi: 10.1016/j.jaci.2023.05.022. Epub 2023 Jun 8. J Allergy Clin Immunol. 2023. PMID: 37301410 Free PMC article.
Anti-CXCR4 Antibody Combined With Activated and Expanded Natural Killer Cells for Sarcoma Immunotherapy.
Vela M, Bueno D, González-Navarro P, Brito A, Fernández L, Escudero A, Valentín J, Mestre-Durán C, Arranz-Álvarez M, Pérez de Diego R, Mendiola M, Pozo-Kreilinger JJ, Pérez-Martínez A. Vela M, et al. Among authors: mestre duran c. Front Immunol. 2019 Aug 2;10:1814. doi: 10.3389/fimmu.2019.01814. eCollection 2019. Front Immunol. 2019. PMID: 31428099 Free PMC article.
SARS-CoV-2-Specific Memory T Lymphocytes From COVID-19 Convalescent Donors: Identification, Biobanking, and Large-Scale Production for Adoptive Cell Therapy.
Ferreras C, Pascual-Miguel B, Mestre-Durán C, Navarro-Zapata A, Clares-Villa L, Martín-Cortázar C, De Paz R, Marcos A, Vicario JL, Balas A, García-Sánchez F, Eguizabal C, Solano C, Mora-Rillo M, Soria B, Pérez-Martínez A. Ferreras C, et al. Among authors: mestre duran c. Front Cell Dev Biol. 2021 Feb 25;9:620730. doi: 10.3389/fcell.2021.620730. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 33718360 Free PMC article.
Donor selection for adoptive cell therapy with CD45RA- memory T cells for patients with coronavirus disease 2019, and dexamethasone and interleukin-15 effects on the phenotype, proliferation and interferon gamma release.
Al-Akioui-Sanz K, Pascual-Miguel B, Díaz-Almirón M, Mestre-Durán C, Navarro-Zapata A, Clares-Villa L, Martín-Cortázar C, Vicario JL, Moreno MÁ, Balas A, De Paz R, Minguillón J, Pérez-Martínez A, Ferreras C. Al-Akioui-Sanz K, et al. Among authors: mestre duran c. Cytotherapy. 2023 Mar;25(3):330-340. doi: 10.1016/j.jcyt.2022.12.001. Epub 2022 Dec 12. Cytotherapy. 2023. PMID: 36585293 Free PMC article.
Ruxolitinib does not completely abrogate the functional capabilities of TLR4/9 ligand-activated NK cells.
Mestre-Durán C, Martín-Cortázar C, García-Solís B, Pernas A, Pertíñez L, Galán V, Sisinni L, Clares-Villa L, Navarro-Zapata A, Al-Akioui K, Escudero A, Ferreras C, Pérez-Martínez A. Mestre-Durán C, et al. Front Immunol. 2023 Jan 5;13:1045316. doi: 10.3389/fimmu.2022.1045316. eCollection 2022. Front Immunol. 2023. PMID: 36685552 Free PMC article.
NKG2D-CAR memory T cells target pediatric T-cell acute lymphoblastic leukemia in vitro and in vivo but fail to eliminate leukemia initiating cells.
Ibáñez-Navarro M, Fernández A, Escudero A, Esteso G, Campos-Silva C, Navarro-Aguadero MÁ, Leivas A, Caracuel BR, Rodríguez-Antolín C, Ortiz A, Navarro-Zapata A, Mestre-Durán C, Izquierdo M, Balaguer-Pérez M, Ferreras C, Martínez-López J, Valés-Gómez M, Pérez-Martínez A, Fernández L. Ibáñez-Navarro M, et al. Among authors: mestre duran c. Front Immunol. 2023 Oct 18;14:1187665. doi: 10.3389/fimmu.2023.1187665. eCollection 2023. Front Immunol. 2023. PMID: 37928520 Free PMC article.
Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE).
Pérez-Martínez A, Mora-Rillo M, Ferreras C, Guerra-García P, Pascual-Miguel B, Mestre-Durán C, Borobia AM, Carcas AJ, Queiruga-Parada J, García I, Sánchez-Zapardiel E, Gasior M, De Paz R, Marcos A, Vicario JL, Balas A, Moreno MA, Eguizabal C, Solano C, Arribas JR, Buckley RM, Montejano R, Soria B. Pérez-Martínez A, et al. Among authors: mestre duran c. EClinicalMedicine. 2021 Sep;39:101086. doi: 10.1016/j.eclinm.2021.101086. Epub 2021 Aug 13. EClinicalMedicine. 2021. PMID: 34405140 Free PMC article.
Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity.
Mozo Y, Bueno D, Sisinni L, Fernández-Arroyo A, Rosich B, Martínez AP, Benítez-Carabante MI, Alonso L, Uría ML, Heredia CD, Mestre-Duran C, Pascual CFB, Torres J, Losantos I, Escudero A, Ruz-Caracuel B. Mozo Y, et al. Among authors: mestre duran c. Pediatr Hematol Oncol. 2021 May;38(4):331-345. doi: 10.1080/08880018.2020.1868637. Epub 2021 Mar 4. Pediatr Hematol Oncol. 2021. PMID: 33661711